Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2011 February;102(1) > Minerva Medica 2011 February;102(1):79-92

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

REVIEWS  


Minerva Medica 2011 February;102(1):79-92

language: Italian

Mucositis in oncohematology

Niscola P. 1, Tendas A. 1, Giovannini M. 1, Scaramucci L. 1, De Sanctis V. 2, Cupelli L. 1, De Fabritiis P. 1

1 Unità Operativa di Ematologia, Ospedale Sant’Eugenio, Roma, Italia;
2 Dipartimento di Radioterapia, Università “La Sapienza”, Roma, Italia


PDF  


Mucositis is the result of the cytotoxic effects of many treatments given for hematological malignancies (HMs); it represents a major source of potentially devastating clinical complications and portrays negative consequences on the patient’s management, such as a longer hospitalization, the need of analgesic and total parenteral nutrition use, and increased costs. The available measures for the prevention and treatment of mucositis have been substantially palliative, being limited to the control of pain, infection, bleeding and nutrition. However, in the last decade, a better insight into the complex pathogenesis of MBI has led to the development of novel therapeutic options, such as palifermin, which can provide tools potentially allowing a targeted approach to mucositis.

top of page

Publication History

Cite this article as

Corresponding author e-mail

niscola.pasquale@aslrmc.it